Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

Juventas Therapeutics

Status and phase: Completed; Phase 2

Conditions: Critical Limb Ischemia

Treatments: Biological: JVS-100(4 mg) or placebo/8 injections; Biological: JVS-100(16 mg) or placebo/16 injections; Biological: JVS-100(8 mg) or placebo/16 injections; Biological: JVS-100(8 mg) or placebo/8 injections

Study type: Interventional

Funder types: Industry

Identifiers

NCT01410331

JTCS-002

Details and patient eligibility

About

This is a double-blind, placebo controlled study designed to evaluate the safety and efficacy of JVS-100 given to adult subjects with critical limb ischemia (CLI).

Full description

48 subjects diagnosed with Rutherford Class 4-5 Critical Limb Ischemia (CLI) with non-healing ulcers and/or ischemic rest pain will be enrolled in this study designed to investigate the safety and efficacy of JVS-100. JVS-100 will be delivered by direct intramuscular injection into the limbs of study subjects. Subjects will be randomized to receive a single set of direct intramuscular injections of either JVS-100 or vehicle control and will be followed for 12 months post dosing. Safety and efficacy assessments will be collected at 3 days, 4 weeks and 3, 6 and 12 months.

Enrollment: 48 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women 40 years of age or older
• Rutherford Category 4 or 5
• Ankle systolic pressure of 70mmHg or less, or toe pressure of 50mmHg or less
• Poor option for surgical revascularization by open or endovascular strategies
• Those diabetic subjects who are on optimal diabetes treatment, with HbA1c <8.5 %
• Subject should be on stable therapy for the treatment of CLI, including statin and antiplatelet therapy
• Subject must be willing to forgo treatment with hyperbaric oxygen, nerve stimulation, ot sympathectomy for treatment of CLI 10 days prior to 45 days following injection of study drug

Exclusion criteria

• Life expectancy of less than 1 year
• Previous major amputation of the leg to be treated or planned major amputation within the first month following enrollment
• Patent revascularization (within 6 weeks)in the leg to be treated prior to enrollment
• NYHA Class IV heart failure
• Evidence of osteomyelitis or active infection
• Subjects with Buerger's Disease
• Subjects with a history of Systemic Lupus Erythematosus (SLE) flare
• Subjects with established chronic kidney (stage 5) requiring dialysis
• Uncontrolled blood pressure
• Significant hepatic disease
• Diabetic subjects with active proliferative retinopathy
• Immunodeficient states or subjects receiving chronic immunosuppressive therapy
• Any patient with a history of cancer unless 1)the cancer was limited to curable non-melanoma skin malignancies, or 2)the cancer was removed by successful tumor resection, with or without radiation or chemotherapy, 5 years or more prior to enrollment in this study without recurrence
• Pregnant or lactating women or subjects of childbearing potential not protected by an effective method of birth control
• Men unwilling to agree to barrier contraception or limit sexual activity
• Presence of any other condition that, in the opinion of the investigator, might compromise any aspect of the trial
• Acute coronary syndrome within 3 month prior to enrollment
• Previous treatment with angiogenic growth factors or with stem cell therapy within 1 year
• Participation in another clinical trial in the last 30 days
• Clinically significant elevations in PT/PTT/INR
• Non-heel wound size >20 cm2 (excluding toe gangrene) or heel wound size >10cm2 on the index limb
• History of drug or alcohol abuse in the last year

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

48 participants in 4 patient groups

Cohort 1

Experimental group

Description:

Subjects will be randomized to receive either 4 mg of JVS-100 or placebo over 8 injections.

Treatment:

Biological: JVS-100(4 mg) or placebo/8 injections

Cohort 2

Experimental group

Description:

Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 8 injections.

Treatment:

Biological: JVS-100(8 mg) or placebo/8 injections

Cohort 3

Experimental group

Description:

Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 16 injections.

Treatment:

Biological: JVS-100(8 mg) or placebo/16 injections

Cohort 4

Experimental group

Description:

Subjects will be randomized to receive either 16 mg of JVS-100 or placebo over 16 injections.

Treatment:

Biological: JVS-100(16 mg) or placebo/16 injections